Vaxart to Host Webcast with Crucial Opinion Leaders to Go over the Wellness Influence and Illness Burden for Norovirus

Vaxart, Inc.

Organization to give a detailed overview of its norovirus clinical system

Webcast to be held on March 28, 2023 at 1:00 p.m. ET

SOUTH SAN FRANCISCO, Calif., March 17, 2023 (GLOBE NEWSWIRE) — Vaxart, Inc. (NASDAQ: VXRT) currently announced it will host a important opinion leader video webcast on the well being and financial effect and illness burden for norovirus on Tuesday, March 28, 2023 at 1:00 p.m. ET.

The webcast will function presentations by prominent norovirus illness professionals Jan Vinjé, Ph.D., Head, National Calicivirus Laboratory, Centers for Illness Handle &amp Prevention, and Sarah Bartsch, Project Director, Public Wellness Informatics, Computational, and Operations Investigation, Investigation Foundation of the City University of New York.

In addition, Vaxart management will give a detailed overview of the Company’s investigational norovirus oral pill vaccine system, such as its two present Phase two clinical trials:

• An ongoing Phase two GI.1 norovirus challenge study measuring the efficacy and security of our norovirus vaccine candidate. The study is also developed to recognize a correlate of protection amongst immune responses to the vaccine and a reduction in threat of norovirus infection and / or extreme gastroenteritis. The Organization expects to report topline information from this study in Q3 2023.

• A Phase two dose-ranging study of Vaxart’s bivalent norovirus oral vaccine candidate is developed to recognize a vaccine dose for a prospective Phase three clinical trial. The Organization expects to report topline information from this study in mid-2023.

To register for the webcast, please click right here. A replay of the webcast will be obtainable on the Company’s web site at www.vaxart.com following the conclusion of the occasion.

About the KOLs

Jan Vinjé, Ph.D.
Dr. Vinjé is head of the National Calicivirus Laboratory and Director of CaliciNet at the Centers for Illness Handle and Prevention (CDC) in Atlanta, GA. Dr. Vinjé received his Ph.D. degree at the University of Utrecht, the Netherlands, in 1999. Right after getting a postdoctoral fellowship and an appointment as analysis assistant professor at the University of North Carolina in Chapel Hill, he joined CDC in 2006. More than the previous ten years, he has served on various system advisory committees from various European analysis projects (FP6, FP7). He is serving as technical specialist on the norovirus subcommittee of the National Advisory Committee on Microbiological Criteria for Foods and is a member of the International Committee on Taxonomy of Viruses study groups on Caliciviridae (chair as of 2014) and Astroviridae. He is at present a member of the editorial board of the Journal of Clinical Microbiology and associate editor of the journal Meals and Environmental Virology, and he serves as an ad hoc reviewer for several higher-effect journals. Dr. Vinjé has published more than one hundred peer-reviewed publications and various book chapters. His analysis interests contain all elements of viral gastrointestinal illness, such as detection, characterization, and prevention and manage of norovirus infections.

Story continues

Sarah M. Bartsch, MPH
Ms. Bartsch is a Project Director and Senior Analyst with Public Wellness Informatics, Computational, and Operations Investigation (PHICOR), the Artificial Intelligence, Modeling, and Informatics for Nutrition Guidance and Systems (AIMINGS) Center, and the Center for Sophisticated Technologies and Communication in Wellness (CATCH), headquartered at the City University of New York (CUNY) Graduate College of Public Wellness and Wellness Policy. She has been a aspect of the group considering that August of 2009 and has more than a decade of expertise working with systems approaches and establishing mathematical and computational models to help a wide variety of selection makers in public well being. Bartsch has authored more than 95 scientific publications, such as far more than 30 as initially author.

About Vaxart 
Vaxart is a clinical-stage biotechnology firm establishing a variety of oral recombinant vaccines primarily based on its proprietary delivery platform. Vaxart vaccines are developed to be administered working with tablets that can be stored and shipped without the need of refrigeration and get rid of the threat of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is appropriate to provide recombinant vaccines, positioning the firm to create oral versions of at present marketed vaccines and to style recombinant vaccines for new indications. Vaxart’s improvement applications at present contain pill vaccines developed to guard against norovirus, coronavirus, seasonal influenza, and respiratory syncytial virus (RSV), as properly as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s initially immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technologies and creations for oral vaccination working with adenovirus and TLR3 agonists.

Note Relating to Forward-Seeking Statements
This press release includes forward-hunting statements that involve substantial dangers and uncertainties. All statements, other than statements of historical details, integrated in this press release with regards to Vaxart’s technique, prospects, plans and objectives, outcomes from preclinical and clinical trials, commercialization agreements and licenses, and beliefs and expectations of management are forward-hunting statements. These forward-hunting statements might be accompanied by such words as “must,” “think,” “could,” “prospective,” “will,” “anticipated,” “anticipate,” “strategy,” and other words and terms of related which means. Examples of such statements contain, but are not restricted to, statements relating to Vaxart’s capacity to create and commercialize its item candidates, such as its vaccine booster solutions Vaxart’s expectations with regards to clinical outcomes and trial information and Vaxart’s expectations with respect to the effectiveness of its item candidates. Vaxart might not essentially accomplish the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-hunting statements, and you must not location undue reliance on these forward-hunting statements. Actual outcomes or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-hunting statements. A variety of vital elements could lead to actual outcomes or events to differ materially from the forward-hunting statements that Vaxart tends to make.

Please also refer to the dangers described in the “Danger Things” sections of Vaxart’s Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-hunting statements, except as needed by law.

Contacts

Investor Relations:

Andrew Blazier

FINN Partners

IR@vaxart.com

(646) 871-8486